Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The rationale of this study is to assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life settings with a multinational approach, as well as the impact of this improved formulation (with regards to adverse events [AEs]) to subjects' adherence.
| Condition | Intervention |
|---|---|
|
Multiple Sclerosis, Relapsing Remitting |
Drug: Rebif® New Formulation |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif® New Formulation) in Real Life Settings |
- Proportion of subjects with injection site reactions (ISRs) [ Time Frame: Baseline, month 6 and month 12 ] [ Designated as safety issue: Yes ]
- proportion of subjects with AEs and with specific categories of AEs; proportion and reasons of missed injections, annual relapse rate, proportion of relapse-free subjects from baseline, time to first relapse [ Time Frame: Baseline, month 6 and month 12 ] [ Designated as safety issue: Yes ]
| Enrollment: | 256 |
| Study Start Date: | October 2008 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
-
Drug: Rebif® New Formulation
This international, multicentric, prospective, observational study is being conducted to assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life settings in subjects with relapsing remitting multiple sclerosis (RRMS), as well as the impact of this improved formulation (with regards to adverse events [AEs]) to subjects' adherence. Three hundred and fifty subjects from approximately 80 sites across seven countries will be enrolled in the study. Subjects will be treated with IFN beta-1a (Rebif® New Formulation) in real life settings according to the clinical and paraclinical course and laboratory findings as routinely evaluated by the physician. Data related to AEs; subjects' adherence to treatment, reasons for treatment discontinuation; number and reasons of missed injections; and the clinical and paraclinical data on efficacy regarding relapses will be captured. Data will be reported prospectively throughout the duration of the study (12 months) at two visits (at month 6 and month 12) following the initial visit; at baseline, data can be recorded retrospectively from the subjects' medical file. All the data will be evaluated descriptively.
OBJECTIVES
Primary objective
- To assess the local tolerability of Rebif® New Formulation in real life settings with a multinational approach.
Secondary objectives
- To assess the safety profile, subjects' adherence to and efficacy of Rebif® New Formulation
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Subjects diagnsoed with RRMS from approximately 80 sites across seven countries.
Inclusion Criteria:
- Subjects with a diagnosis of RRMS according to the Mc Donald criteria(2005)
- 18 to 60 years of age
- Expanded Disability Status Scale (EDSS) < 6
- Naïve subjects or subjects treated with Rebif® New Formulation for no more than 6 weeks prior to enrollment
- Subjects who have given written informed consent to participate in the study
Exclusion Criteria:
- Primary progressive or secondary progressive MS
- Subjects previously administered IFN beta-1a (including Rebif®) or IFN beta-1b or glatiramer acetate or any other immunomodulatory or immunosuppressive agents or any other MS therapy in the past with the exception of Rebif® New Formulation for no more than 6 weeks prior to enrollment
- Subjects receiving oral or systemic corticosteroids or Adrenocorticotrophic hormone within 30 days of visit 1 (prior to enrolment)
- History of any chronic pain syndrome
- Known allergy to IFN or its excipients
- Serious or acute heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure
- Inadequate liver function, defined by a alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN), or alkaline phosphatase > 2 x ULN, or total bilirubin > 2 x ULN if associated with any elevation of ALT or alkaline phosphatase
- Inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal
- Current or past (within the last 2 years) history of alcohol or drug abuse
- Contra-indications to IFN beta-1a
Contacts and Locations| Greece | |
| Neurology Clinic, General Hospital of Thessaloniki "G. Papanikolaou" | |
| Thessaloniki, Greece, 57010 | |
| Study Director: | Michalis Arvanitis, MD, MSc | Merck A.E., Greece |
More Information
No publications provided
| Responsible Party: | Merck KGaA |
| ClinicalTrials.gov Identifier: | NCT01080027 History of Changes |
| Other Study ID Numbers: | EMR 701068_506 |
| Study First Received: | March 2, 2010 |
| Last Updated: | October 6, 2011 |
| Health Authority: | Portugal: Ethics Committee for Clinical Research Sweden: Regional Ethical Review Board Finland: Ethics Committee Greece: Ethics Committee Norway: Ethics Committee Netherlands: Independent Ethics Committee |
Keywords provided by Merck KGaA:
|
Multiple sclerosis Relapsing remitting Rebif |
Additional relevant MeSH terms:
|
Multiple Sclerosis Sclerosis Multiple Sclerosis, Relapsing-Remitting Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Pathologic Processes Interferon-beta |
Interferons Interferon beta 1a Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Adjuvants, Immunologic |
ClinicalTrials.gov processed this record on May 19, 2013